SUCLA2 and prostate carcinoma: predicts that in malignant prostate cancer cells, the GTP-specific beta subunit of succinyl-CoA synthetase (SUCLG2) is selectively lethal because the alternative route via ATP-specific succinyl-CoA synthetase (SUCLA2) is not present in these cells, creating a selective vulnerability to SUCLG2 knockdown in malignant cells (258).